STUDY AND REPORT ON EFFORTS TO ADDRESS FENTANYL TRAFFICKING FROM THE PEOPLE’S REPUBLIC OF CHINA AND OTHER RELEVANT COUNTRIES.

SEC. 8313. STUDY AND REPORT ON EFFORTS TO ADDRESS FENTANYL TRAFFICKING FROM THE PEOPLE’S REPUBLIC OF CHINA AND OTHER RELEVANT COUNTRIES. (a) Definitions.—In this section: (1) Appropriate committees of congress.—The term “appropriate committees of Congress” means— (A) the Committee on the Judiciary of the Senate; (B) the Committee on Foreign Relations of the Senate; (C) the Committee on Banking, Housing, and Urban Affairs of the Senate; (D) the Committee on the Judiciary of the House of Representatives; (E) the Committee on Foreign Affairs of the House of Representatives; and (F) the Committee on Financial Services of the House of Representatives. (2) DEA.—The term “DEA” means the Drug Enforcement Administration. (3) PRC.—The term “PRC” means the People’s Republic of China. (b) Study and Report on Addressing Trafficking of Fentanyl and Other Synthetic Opioids From the Prc and Other Relevant Countries. Not later than 180 days after the date of the enactment of this Act, the Secretary of State and the Attorney General, in consultation with the Secretary of the Treasury, shall jointly submit to the appropriate committees of Congress an unclassified written report, with a classified annex, that includes— (1) a description of United States Government efforts to gain a commitment from the Government of the PRC to submit unregulated fentanyl precursors, such as 4-AP, to controls; (2) a plan for future steps the United States Government will take to urge the Government of the PRC to combat the production and trafficking of illicit fentanyl and synthetic opioids from the PRC, including the trafficking of precursor chemicals used to produce illicit narcotics in Mexico and in other countries; (3) a detailed description of cooperation by the Government of the PRC to address the role of the PRC financial system and PRC money laundering organizations in the trafficking of fentanyl and synthetic opioid precursors; (4) an assessment of the expected impact that the designation of principal corporate officers of PRC financial institutions for facilitating narcotics-related money laundering would have on PRC money laundering organizations; (5) an assessment of whether the Trilateral Fentanyl Committee, which was established by the United States, Canada, and Mexico during the January 2023 North American Leaders’ Summit, is improving cooperation with law enforcement and financial regulators in Canada and Mexico to combat the role of PRC financial institutions and PRC money laundering organizations in narcotics trafficking; (6) an assessment of the effectiveness of other United States bilateral and multilateral efforts to strengthen international cooperation to address the PRC’s role in the trafficking of fentanyl and synthetic opioid precursors, including through the Global Coalition to Address Synthetic Drug Threats; (7) an update on the status of commitments made by third countries through the Global Coalition to Address Synthetic Drug Threats to combat the synthetic opioid crisis and progress towards the implementation of such commitments; (8) a plan for future steps to further strengthen bilateral and multilateral efforts to urge the Government of the PRC to take additional actions to address the PRC’s role in the trafficking of fentanyl and synthetic opioid precursors, particularly in coordination with countries in East Asia and Southeast Asia that have been impacted by such activities; (9) an assessment of how actions the Government of the PRC has taken since November 15, 2023 has shifted relevant supply chains for fentanyl and synthetic opioid precursors, if at all; and (10) the items described in paragraphs (1) through (4) pertaining to India, Mexico, and other countries the Secretary of State determines to have a significant role in the production or trafficking of fentanyl and synthetic opioid precursors for purposes of this report. (c) Establishment of DEA Offices in the PRC.—Not later than 180 days after the date of the enactment of this Act, the Secretary of State and the Attorney General shall jointly provide to the appropriate committees of Congress a classified briefing on— (1) outreach and negotiations undertaken by the United States Government with the Government of the PRC that was aimed at securing the approval of the Government of the PRC to establish United States Drug Enforcement Administration offices in Shanghai and Guangzhou; (2) the role of the Bureau of International Narcotics and Law Enforcement Affairs in the PRC; and (3) additional efforts to establish new partnerships with provincial-level authorities in the PRC to counter the illicit trafficking of fentanyl, fentanyl analogues, and their precursors.